Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 22 September 2015 | By Zachary Brennan
Following two meetings with drug companies and other stakeholders in July and September, the European Medicines Agency (EMA) says it will publish the first clinical trial reports in mid-2016.
The release of the reports comes as EMA's policy on publishing the data came into effect last January. The new policy applies to clinical reports contained in all marketing-authorization applications submitted on or after 1 January 2015, and includes reports where drugmakers have notified EMA of the withdrawal of a marketing authorization application.
EMA held two meetings to offer more detailed discussions on two guidance documents under development -- one on the identification and redaction of commercially confidential information in the clinical reports and the other on the anonymization of clinical reports, in the context of the new policy.
"EMA emphasized that both guidance documents should be, once finalized, considered 'living' documents that will be updated in light of experience obtained," the agency said in a summary of the July meeting.
In the September meeting with patient associations, academia, representatives of National Competent Authorities and industry associations, EMA presented new technical guidance on the procedures tied to the submission of clinical reports, which included information on how trial materials should be sent to the agency, as well as information on the redaction consultation process and the overall process leading to publication.
The meeting centered on the "evolving nature of anonymization taking account of the objective of data utility and the legal requirements for personal data protection," EMA said.
"On one hand, if large sections of a clinical study report are removed, the risk of re-identification is likely to be very low but data utility will be compromised. On the other hand, if a clinical study report is ‘under’ redacted this could lead to the publication of documents that have a high risk of re-identification," the agency added.
The agency said it will meet in October and consult with the European ombudsman and the European data protection supervisor on further plans for the transparency policy.
In addition to the implementation of EMA's transparency policy, the European Commission, EMA and World Health Organization announced Tuesday that they agreed on 1 September to share more non-public information on the safety, quality and efficacy of already-approved drugs. The information they're sharing includes:
EMA September Stakeholder Meeting
Press Release on Trial Transparency
WHO, EC, EMA Sharing Press Release
Tags: EMA, trial transparency, WHO, European Commission, clinical trial data reports
Regulatory Focus newsletters
All the biggest regulatory news and happenings.